The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2022 | Predictive biomarkers for immunotherapy in upper GI cancers
Kohei Shitara, MD, National Cancer Center Hospital East, Chiba, Japan, discusses a range of predictive biomarkers for the use of immunotherapy in patients with gastric, gastroesophageal junction, and esophageal cancers. Dr Shitara discusses MSI-high status, PD-L1 expression, and tutor mutational burden status as possible biomarkers, as well as talking on the use of combined positive score (CPS). This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
A position of a board member or advisor: Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical, Merck Pharmaceutical, Taiho Pharmaceutical, Novartis, AbbVie, GlaxoSmithKline, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Guardant Health Japan, and Janssen
Honoraria for lectures: Takeda, Janssen and Bristol-Myers Squibb
Clinical research grants: Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, Merck Pharmaceutical, Medi Science, Eisai and Amgen
